-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Rating Lowered to D at TheStreet
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Rating Lowered to D at TheStreet
TheStreet cut shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) from a c- rating to a d rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.
CALT has been the topic of a number of other reports. Kepler Capital Markets assumed coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 16th. They issued a buy rating on the stock. Pareto Securities assumed coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 2nd. They issued a buy rating on the stock.
Get Calliditas Therapeutics AB (publ) alerts:Calliditas Therapeutics AB (publ) Price Performance
Calliditas Therapeutics AB (publ) stock opened at $16.65 on Tuesday. The firm has a market cap of $492.49 million, a PE ratio of -6.69 and a beta of 1.63. Calliditas Therapeutics AB has a 52-week low of $12.55 and a 52-week high of $30.77. The company has a quick ratio of 5.32, a current ratio of 5.32 and a debt-to-equity ratio of 0.64. The company's 50 day moving average is $18.17 and its two-hundred day moving average is $17.78.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Jane Street Group LLC acquired a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 11,543 shares of the company's stock, valued at approximately $221,000. 2.94% of the stock is currently owned by hedge funds and other institutional investors.About Calliditas Therapeutics AB (publ)
(Get Rating)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
See Also
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
TheStreet cut shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) from a c- rating to a d rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.
据The StreetRatingsTable报道，在周二发布给投资者的一份研究报告中，华尔街将Calliditas治疗公司(Publ)(纳斯达克代码：CALT-GET评级)的股票从C评级下调至D评级。
CALT has been the topic of a number of other reports. Kepler Capital Markets assumed coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 16th. They issued a buy rating on the stock. Pareto Securities assumed coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 2nd. They issued a buy rating on the stock.
CALT一直是其他一些报告的主题。开普勒资本市场在6月16日星期四的一份研究报告中对Calliditas Treateutics AB(Publ)的股票进行了报道。他们对这只股票发布了买入评级。帕累托证券在6月2日星期四的一份研究报告中承担了对Calliditas Treateutics AB(Publ)股票的报道。他们对这只股票发布了买入评级。
Calliditas Therapeutics AB (publ) Price Performance
Calliditas Treateutics AB(Publ)价格表现
Calliditas Therapeutics AB (publ) stock opened at $16.65 on Tuesday. The firm has a market cap of $492.49 million, a PE ratio of -6.69 and a beta of 1.63. Calliditas Therapeutics AB has a 52-week low of $12.55 and a 52-week high of $30.77. The company has a quick ratio of 5.32, a current ratio of 5.32 and a debt-to-equity ratio of 0.64. The company's 50 day moving average is $18.17 and its two-hundred day moving average is $17.78.
周二，Calliditas Treateutics AB(Publ)的股票开盘报16.65美元。该公司市值为4.9249亿美元，市盈率为-6.69，贝塔系数为1.63。Calliditas Treateutics AB的52周低点为12.55美元，52周高点为30.77美元。该公司的速动比率为5.32，流动比率为5.32，债务权益比率为0.64。该公司的50日移动均线切入位在18.17美元，200日移动均线切入位在17.78美元。
Institutional Inflows and Outflows
机构资金流入和流出
About Calliditas Therapeutics AB (publ)
关于Calliditas Treateutics AB(Publ)
(Get Rating)
(获取评级)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Calliditas Treateutics AB(Publ)是一家临床阶段的生物制药公司，专注于识别、开发和商业化用于孤儿适应症治疗的药物产品，最初的重点是肾脏和肝脏疾病。它提供Nefecon，一种口服布地奈德制剂，是一种治疗自身免疫性肾病免疫球蛋白A肾病的免疫抑制剂。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于Calliditas Treateutics AB(Publ)(CALT)的研究报告
- MarketBeat：回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏，这些股票可能表现优异
- DocuSign是否即将发生重大逆转？
- 石油和天然气股票：投资可再生能源的安全途径
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Calliditas Treateutics AB(Publ)Daily的新闻和评级-在下面输入您的电子邮件地址，以通过MarketBeat.com的免费每日电子邮件时事通讯接收对Calliditas Treateutics AB(Publ)和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧